PerspectiveVaccines

Design of vaccine efficacy trials during public health emergencies

See allHide authors and affiliations

Science Translational Medicine  03 Jul 2019:
Vol. 11, Issue 499, eaat0360
DOI: 10.1126/scitranslmed.aat0360

Article Information

vol. 11 no. 499

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication January 19, 2018
  • Accepted for publication December 13, 2018
  • .

Author Information

  1. Natalie E. Dean1,*,
  2. Pierre-Stéphane Gsell2,
  3. Ron Brookmeyer3,
  4. Victor De Gruttola4,
  5. Christl A. Donnelly5,6,
  6. M. Elizabeth Halloran7,8,
  7. Momodou Jasseh9,
  8. Martha Nason10,
  9. Ximena Riveros2,
  10. Conall H. Watson11,
  11. Ana Maria Henao-Restrepo2 and
  12. Ira M. Longini1,*
  1. 1Department of Biostatistics, University of Florida, Gainesville, FL, USA.
  2. 2World Health Organization, Geneva, Switzerland.
  3. 3Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, USA.
  4. 4Department of Biostatistics, Harvard University, Boston, MA, USA.
  5. 5Department of Statistics, University of Oxford, Oxford, UK.
  6. 6MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.
  7. 7Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  8. 8Department of Biostatistics, University of Washington, Seattle, WA, USA.
  9. 9Medical Research Council, The Gambia at London School of Hygiene and Tropical Medicine, Fajara, The Gambia.
  10. 10Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
  11. 11Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
  1. *Corresponding author. Email: nataliedean{at}ufl.edu (N.E.D.); ilongini{at}ufl.edu (I.M.L.)

Altmetric

Article usage

Article usage: July 2019 to August 2019

AbstractFullPdf
Jul 20193317546295
Aug 2019694820